Giao dịch Corvus Pharmaceuticals, Inc. - CRVS CFD

Điều kiện giao dịch

• Loại: CFD
• Chênh lệch: 0.0632
• Điều chỉnh phí tài trợ qua đêm cho vị thế mua: -0.02151%
• Điều chỉnh phí tài trợ qua đêm cho vị thế bán: -0.00071%
• Thời gian điều chỉnh phí tài trợ qua đêm: 22:00 (UTC)
• Tiền tệ: USD
• Số lượng giao dịch tối thiểu: 10
• Biên lợi nhuận: 5.00%
• Sàn giao dịch chứng khoán: United States of America
• Phí hoa hồng giao dịch: 0%
• Bảo đảm dừng phí bảo hiểm: 1%

Số liệu thống kê chính

• Trước đó Đóng: 22.0884
• Mở: 25.2084
• Thay đổi 1 năm: 384%
• Phạm vi trong ngày: 24.2384 - 26.1584

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and activate various immune cells, as Phase III clinical trial of CPI-006 for COVID-19. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/II clinical trial for adenosine, an immune checkpoint. Its preclinical stage products include CPI-182, an antibody to block neutrophil function and migration, and myeloid derived suppressor cells; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.